Quantity of qualified sufferers: CDEC talked over the uncertainty in the volume of clients with reasonably intense to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some clients who are categorized as acquiring moderate or average illness may have a critical bleeding ph